Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Nasopharyngeal Carcinoma
NCT05352321Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Local Regional Relapse-Free Survival at 3 years. Started Jun 2022; status: recruiting.
Beyond the preview
Go deeper on NCT05352321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05352321.